View in EDS

Oral human papillomavirus (HPV) prevalence and genotyping among healthy adult populations in the United States and Europe: results from the PROGRESS (PRevalence of Oral hpv infection, a Global aSSessment) study.

Saved in:
Bibliographic Details
Title: Oral human papillomavirus (HPV) prevalence and genotyping among healthy adult populations in the United States and Europe: results from the PROGRESS (PRevalence of Oral hpv infection, a Global aSSessment) study.
Authors: Alemany L; Catalan Institute of Oncology. ICO, L'Hospitalet, Barcelona, Spain.; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.; CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain., Felsher M; Merck & Co., Inc., Rahway, NJ, 07065, USA., Giuliano AR; Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive Tampa, Florida, USA, 33612., Waterboer T; German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany., Mirghani H; Hôpital Européen Georges-Pompidou, Assistance Publique - Hôpitaux de Paris, Université Paris Cité, 20 Rue Leblanc, 75015, Paris, France., Mehanna H; Institute of Head & Neck Studies and Education (InHANSE), University of Birmingham, Robert Aitken Building, Vincent Drive, B15 2TT, Birmingham, United Kingdom., Roberts C; Merck & Co., Inc., Rahway, NJ, 07065, USA., Chen YT; Merck & Co., Inc., Rahway, NJ, 07065, USA., Lara N; IQVIA, Provença, 392, 3rd Floor, 08025, Barcelona, Spain., Lynam M; IQVIA, Provença, 392, 3rd Floor, 08025, Barcelona, Spain., Torres M; IQVIA, Provença, 392, 3rd Floor, 08025, Barcelona, Spain., Pedrós M; IQVIA, Provença, 392, 3rd Floor, 08025, Barcelona, Spain., Sanchez E; IQVIA, Provença, 392, 3rd Floor, 08025, Barcelona, Spain., Spitzer J; Merck & Co., Inc., Rahway, NJ, 07065, USA., Sirak B; Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive Tampa, Florida, USA, 33612., Quirós B; Catalan Institute of Oncology. ICO, L'Hospitalet, Barcelona, Spain.; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.; CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain., Carretero G; Catalan Institute of Oncology. ICO, L'Hospitalet, Barcelona, Spain.; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.; CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain., Paytubi S; Catalan Institute of Oncology. ICO, L'Hospitalet, Barcelona, Spain.; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.; CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain., Morais E; MSD France, Puteaux, France., Pavón MA; Catalan Institute of Oncology. ICO, L'Hospitalet, Barcelona, Spain.; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.; CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Source: EClinicalMedicine [EClinicalMedicine] 2025 Jan 15; Vol. 79, pp. 103018. Date of Electronic Publication: 2025 Jan 15 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: The Lancet Country of Publication: England NLM ID: 101733727 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-5370 (Electronic) Linking ISSN: 25895370 NLM ISO Abbreviation: EClinicalMedicine Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2589-5370
DOI:10.1016/j.eclinm.2024.103018